Published On: Mon, Jun 19th, 2017

Reviewing Individual Broker Targets Of Amicus Therapeutics, Inc. (FOLD)


Recently stock market analysts have updated their consensus ratings on shares of Amicus Therapeutics, Inc. (FOLD).

Most recent broker ratings

05/31/2017 – Amicus Therapeutics, Inc. had its “buy” rating reiterated by analysts at Chardan Capital. They now have a USD 12.5 price target on the stock.

05/24/2017 – Amicus Therapeutics, Inc. had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 10 price target on the stock.

05/22/2017 – Amicus Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Robert W. Baird. They now have a USD 12 price target on the stock.

03/30/2017 – Amicus Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 15 price target on the stock.

11/29/2016 – Amicus Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 12 price target on the stock.

11/29/2016 – Amicus Therapeutics, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 11 price target on the stock.

03/30/2016 – Amicus Therapeutics, Inc. had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 10 price target on the stock.

03/08/2016 – Amicus Therapeutics, Inc. was upgraded to “buy” by analysts at Janney Montgomery Scott.

06/16/2015 – Amicus Therapeutics, Inc. had its “buy” rating reiterated by analysts at B. Riley. They now have a USD 17.5 price target on the stock.

05/08/2015 – Amicus Therapeutics, Inc. was downgraded to “sell” by analysts at Zacks.

Amicus Therapeutics, Inc. has a 50 day moving average of 7.93 and a 200 day moving average of 6.70. The stock’s market capitalization is 1.35B, it has a 52-week low of 4.41 and a 52-week high of 9.61.

The share price of the company (FOLD) was up +7.28% during the last trading session, with a high of 9.48 and the volume of Amicus Therapeutics, Inc. shares traded was 4713439.

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.